Juvenile idiopathic arthritis in infants with Harlequin Ichthyosis: two cases report and literature review.

Acitretin Case report Harlequin Ichthyosis Juvenile idiopathic arthritis Oral retinoids

Journal

Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759

Informations de publication

Date de publication:
15 Apr 2020
Historique:
received: 11 03 2020
accepted: 07 04 2020
entrez: 16 4 2020
pubmed: 16 4 2020
medline: 3 3 2021
Statut: epublish

Résumé

Harlequin Ichthyosis is the most severe variant of congenital autosomal recessive ichthyosis, associated with severe morbidity and potentially lethal in early life. At birth, patients present thick and plaque-like scales all over the body, with consequent cutaneous and extra-cutaneous complications, such as poor thermoregulation, recurrent infections, pain, electrolytes imbalance and joint contractures. Juvenile Idiopathic Arthritis usually manifests before the age of 16 years and persists for more than 6 weeks. The association between these two pathologies has been described in the literature as a very rare event, which creates diagnostic and therapeutic challenge. We describe two patients affected by Harlequin Ichthyosis who early developed Juvenile Idiopathic Arthritis. Both patients were treated with retinoids, ibuprofen and long-acting intra-articular glucocorticoids; due to polyarticular involvement, one child was also treated with weekly oral methotrexate. The association between Harlequin Ichthyosis and Juvenile Idiopathic Arthritis is rare and the pathophysiological mechanism that binds them is still unknown. Nonetheless caregivers should be aware of the possible occurrence of Juvenile Idiopathic Arthritis at very early ages in children affected by Harlequin Ichthyosis.

Sections du résumé

BACKGROUND BACKGROUND
Harlequin Ichthyosis is the most severe variant of congenital autosomal recessive ichthyosis, associated with severe morbidity and potentially lethal in early life. At birth, patients present thick and plaque-like scales all over the body, with consequent cutaneous and extra-cutaneous complications, such as poor thermoregulation, recurrent infections, pain, electrolytes imbalance and joint contractures. Juvenile Idiopathic Arthritis usually manifests before the age of 16 years and persists for more than 6 weeks. The association between these two pathologies has been described in the literature as a very rare event, which creates diagnostic and therapeutic challenge.
CASE PRESENTATION METHODS
We describe two patients affected by Harlequin Ichthyosis who early developed Juvenile Idiopathic Arthritis. Both patients were treated with retinoids, ibuprofen and long-acting intra-articular glucocorticoids; due to polyarticular involvement, one child was also treated with weekly oral methotrexate.
CONCLUSIONS CONCLUSIONS
The association between Harlequin Ichthyosis and Juvenile Idiopathic Arthritis is rare and the pathophysiological mechanism that binds them is still unknown. Nonetheless caregivers should be aware of the possible occurrence of Juvenile Idiopathic Arthritis at very early ages in children affected by Harlequin Ichthyosis.

Identifiants

pubmed: 32293521
doi: 10.1186/s13052-020-0817-5
pii: 10.1186/s13052-020-0817-5
pmc: PMC7158043
doi:

Types de publication

Case Reports Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

44

Références

Int J Dermatol. 2018 Apr;57(4):428-433
pubmed: 29377090
J Rheumatol. 2015 Mar;42(3):521-6
pubmed: 25320218
Pediatrics. 2017 Jan;139(1):
pubmed: 27999114
Hip Int. 2011 Jul-Aug;21(4):487-9
pubmed: 21936072
J Womens Health (Larchmt). 2004 Oct;13(8):939-53
pubmed: 15671709
J Am Acad Dermatol. 2013 Nov;69(5):808-809
pubmed: 24124810
JAMA Dermatol. 2018 Jul 1;154(7):847-849
pubmed: 29710282
Clin Rheumatol. 2007 Mar;26(3):460-2
pubmed: 17119860
Br J Dermatol. 2019 Feb;180(2):272-281
pubmed: 30216406
Pediatr Dermatol. 2003 Sep-Oct;20(5):421-6
pubmed: 14521561
Br J Dermatol. 2006 Feb;154(2):267-76
pubmed: 16433796
Arch Dermatol. 2011 Jun;147(6):681-6
pubmed: 21339420
J Am Acad Dermatol. 2014 Feb;70(2):387-8
pubmed: 24438961
Pediatrics. 2015 Aug;136(2):e333-43
pubmed: 26195533
Lancet. 2007 Mar 3;369(9563):767-778
pubmed: 17336654
Am J Hum Genet. 2005 May;76(5):794-803
pubmed: 15756637
Hum Mol Genet. 1996 Oct;5(10):1649-55
pubmed: 8894702
Br J Dermatol. 2019 Mar;180(3):484-495
pubmed: 29897631
Dermatoendocrinol. 2011 Apr;3(2):107-12
pubmed: 21695020
Cell Tissue Res. 2013 Feb;351(2):281-8
pubmed: 22864982
Br J Dermatol. 1996 Jun;134(6):1023-9
pubmed: 8763418
Dermatol Ther. 2013 Jan-Feb;26(1):1-15
pubmed: 23384016
J Dermatol Sci. 2006 May;42(2):83-9
pubmed: 16481150
Ann Rheum Dis. 2009 Jul;68(7):1159-64
pubmed: 18957482
Arthritis Rheumatol. 2019 Jun;71(6):1000-1010
pubmed: 30592383

Auteurs

Cinzia Auriti (C)

Department of Medical and Surgical Neonatology, Bambino Gesù Children's Hospital, IRCSS, Piazza S. Onofrio 4, 00165, Rome, Italy. cinzia.auriti@opbg.net.

Roberta Rotunno (R)

Pediatric Dermatology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Andrea Diociaiuti (A)

Pediatric Dermatology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Silvia Magni Manzoni (SM)

Rheumatology Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Andrea Uva (A)

Rheumatology Division, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Pediatrics Department, Umberto I Hospital, La Sapienza University, Rome, Italy.

Iliana Bersani (I)

Department of Medical and Surgical Neonatology, Bambino Gesù Children's Hospital, IRCSS, Piazza S. Onofrio 4, 00165, Rome, Italy.

Alessandra Santisi (A)

Department of Medical and Surgical Neonatology, Bambino Gesù Children's Hospital, IRCSS, Piazza S. Onofrio 4, 00165, Rome, Italy.

Andrea Dotta (A)

Department of Medical and Surgical Neonatology, Bambino Gesù Children's Hospital, IRCSS, Piazza S. Onofrio 4, 00165, Rome, Italy.

May El Hachem (M)

Pediatric Dermatology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH